Esra Ergun Alis

Dr. Esra Ergun Alis


Research Focus & Metrics

Academic Career Length

16Years (2011-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
9 November 2021 in American Journal of Gastroenterology
Verified
Journal Article
Open access
Giovanni MarascoGiovanni Marasco
Giovanni Marasco
CCCesare Cremon
Cesare Cremon
MBMaria Raffaella Barbaro
Maria Raffaella Barbaro
DSDaniele Salvi
Daniele Salvi
GCGiulia Cacciari
Giulia Cacciari
TGthe GI-COVID19 Study Group
the GI-COVID19 Study Group
INTRODUCTION: Gastrointestinal (GI) symptoms in coronavirus-19 disease (COVID-19) have been reported with great variability and without standardization. In hospitalized patients, we aimed to evaluate the prevalence of GI symptoms, factors associated with their occurrence, and variation at 1 month. METHODS: The GI-COVID-19 is a prospective, multicenter, controlled study. Patients with and without COVID-19 diagnosis were recruited at hospital admission and asked for GI symptoms at admission and after 1 month, using the validated Gastrointestinal Symptom Rating Scale questionnaire. RESULTS: The study included 2036 hospitalized patients. A total of 871 patients (575 COVID+ and 296 COVID−) were included for the primary analysis. GI symptoms occurred more frequently in patients with COVID-19 (59.7%; 343/575 patients) than in the control group (43.2%; 128/296 patients) (P < 0.001). Patients with COVID-19 complained of higher presence or intensity of nausea, diarrhea, loose stools, and urgency as compared with controls. At a 1-month follow-up, a reduction in the presence or intensity of GI symptoms was found in COVID-19 patients with GI symptoms at hospital admission. Nausea remained increased over controls. Factors significantly associated with nausea persistence in COVID-19 were female sex, high body mass index, the presence of dyspnea, and increased C-reactive protein levels. DISCUSSION: The prevalence of GI symptoms in hospitalized patients with COVID-19 is higher than previously reported. Systemic and respiratory symptoms are often associated with GI complaints. Nausea may persist after the resolution of COVID-19 infection.


13 December 2020 in Medicina
Verified
Journal Article
Open access
PDF file
SÖSinem Özyılmaz
Sinem Özyılmaz
EAEsra Ergun Alis
Esra Ergun Alis
EEEmrah Ermiş
Emrah Ermiş
SASamir Allahverdiyev
Samir Allahverdiyev
HUHakan Uçar
Hakan Uçar
Background and Objectives: This study aimed to evaluate the relationship between mortality and cardiac laboratory findings in patients who were hospitalized after a positive PCR for COVID-19 infection. Materials and Methods: This study included patients who were admitted to or referred to the hospital between 20 March and 20 June 2020, diagnosed with COVID-19 via a positive RT-PCR from nasal and pharyngeal swab samples. The troponin I level was measured from each patient. Medical records of patients were retrospectively reviewed and analyzed. Results: A hundred and five patients who were diagnosed with COVID-19 and hospitalized, or who died in the hospital due to COVID-19, were included in this study. There was a statistically significant difference between the troponin I high and low level groups in terms of age (years), BMI, shortness of breath (SB), oxygen saturation (%), hypertension, length of stay in the ICU; and for mortality, C-reactive protein, the neutrophil-to-lymphocyte ratio, hemoglobin, lactate dehydrogenase, ferritin, D-dimer, creatine kinase-MB, prothrombin time, calcium, and 25-hydroxy vitamin 25(OH)D3 (all p < 0.05). In the logistic analyses, a significant association was noted between troponin I and the adjusted risk of mortality. A ROC curve analysis identified troponin I values > 7.8 pg/mL as an effective cut-off point in mortality for patients with COVID-19. A troponin I value of higher than 7.8 pg/mL yielded a sensitivity of 78% and a specificity of 86%. Conclusions: The hospital mortality rate was higher among patients diagnosed with COVID-19 accompanied by troponin levels higher than 7.8 pg/mL. Therefore, in patients diagnosed with COVID-19, elevated troponin I levels >7.8 pg/mL can be considered an independent risk factor for mortality.

17 October 2025 in Biomedicines
Verified
Journal Article
Open access
PDF file
IKIlker Kolbas
Ilker Kolbas
BUBerivan Karatekin Usta
Berivan Karatekin Usta
EAEsra Ergun Alis
Esra Ergun Alis
ICIrfan Cicin
Irfan Cicin
Background: Distinguishing expected postoperative inflammation from early infection remains challenging after thoracic surgery; serial C-reactive protein (CRP) is widely used to aid this differentiation. Methods: We conducted a single-centre retrospective cohort study of adults undergoing thoracic surgery (1 January 2022–31 December 2024). CRP was measured preoperatively and on postoperative days (POD) 1–5; trajectories were compared by surgical approach and extent of resection using repeated-measures ANOVA with Greenhouse–Geisser correction (α = 0.05). Results: Among 144 patients (VATS n = 79; open thoracotomy n = 65; extent: segmentectomy n = 25, lobectomy n = 96, bilobectomy n = 9, pneumonectomy n = 14), overall CRP rose from 26.6 ± 45.0 mg/L preoperatively to a POD2 peak of 200.9 ± 72.7 mg/L, then declined to 118.1 ± 70.7 mg/L by POD5. Thoracotomy showed higher peaks than VATS (POD2 216.1 ± 76.0 vs. 152.3 ± 29.9 mg/L; POD3 206.7 ± 88.7 vs. 159.8 ± 72.4 mg/L), but time × approach was not statistically significant (F = 1.042, p = 0.381; partial η2 = 0.115). The extent analysis showed the highest peaks with pneumonectomy (POD2 273.7 ± 46.3 mg/L) compared with bilobectomy (155.7 ± 11.0 mg/L) and lobectomy (VATS 132.1 ± 3.7, open 196.8 ± 85.3 mg/L); time × extent was not significant (F = 1.136, p = 0.384; partial η2 = 0.299). The overall effect of time did not reach significance (F = 1.127, p = 0.352; partial η2 = 0.124), reflecting variability. Patients with clinically diagnosed infections exhibited more prolonged CRP elevation, often >100 mg/L beyond POD4, whereas uncomplicated cases declined after the POD2 peak; these trends did not achieve statistical significance in this cohort. Conclusions: Early postoperative CRP in thoracic surgery typically peaks at 48–72 h and then falls. Higher peaks with open surgery and more extensive resection were observed but not statistically confirmed; persistence > 100 mg/L after POD3–4 may flag complications. Prospective studies are needed to validate thresholds and refine CRP-based surveillance pathways.

9 April 2025 in Occupational Therapy In Health Care
Verified
Journal Article
Closed access
VFVildan Fidanoglu
Vildan Fidanoglu
MSMelda Saglam
Melda Saglam
SPserkan pekcetin
serkan pekcetin
NYNaciye Vardar Yagli
Naciye Vardar Yagli
BYBirsen Pinar Yildiz
Birsen Pinar Yildiz
EAEsra Ergun Alis
Esra Ergun Alis
The Sars-Cov-2 infection disease (COVID-19) causes symptoms during both acute and post-COVID phases. This study assessed exercise capacity and occupational competence of 20 hospitalized COVID-19 patients, at discharge and three months later using the 6-Minute Step Test and Occupational Self-Assessment. Significant differences were found in both exercise capacity and occupational competence scores between discharge and three months later (p < 0.05). However, these measurements were not correlated (p > 0.05). Although patients show improvement after discharge, some symptoms persisted, affecting their exercise, and occupational performance. Further research is needed to explore long-term occupational outcomes of COVID-19 beyond one year.